ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0678

Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually

Oliver Distler1, Margarida Alves2, Gerrit Toenges3 and Anna-Maria Hoffmann-Vold4, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 4Oslo University Hospital, Oslo, Norway

Meeting: ACR Convergence 2024

Keywords: , , , ,

Session Information

Date: Saturday, November 16, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year is often used in clinical practice. We used data from clinical trials to evaluate ILD progression at time-points up to 1 year in patients with systemic sclerosis-associated ILD (SSc-ILD) and rheumatoid arthritis-associated ILD (RA-ILD).

Methods: We analyzed data from patients with fibrosing SSc-ILD who received placebo in the SENSCIS trial and patients with progressive fibrosing RA-ILD who received placebo in the INBUILD trial. We assessed the proportions of patients with ILD progression (absolute decline in FVC % predicted ≥5% or death) at weeks 2, 4, 6, 12, 24, 36 and 52. A worst observation carried forward approach was used to impute missing FVC values in the evaluation of a patient’s progression status at each time point. Time to ILD progression over 52 weeks was estimated using the Kaplan-Meier method.

Results: Among patients with SSc-ILD in the SENSCIS trial (n=288), mean (SD) time since SSc-ILD diagnosis was 2.6 (1.8) years and mean (SD) FVC at baseline was 72.7 (16.6) % predicted. The proportions of patients with SSc-ILD progression at weeks 2, 4, 6, 12, 24, 36 and 52 were 7.6%, 11.1%, 11.1%, 16.3%, 25.0%, 30.9% and 36.5%. Among patients with RA-ILD in the INBUILD trial (n=47), mean (SD) time since RA-ILD diagnosis was 3.7 (3.5) years and mean (SD) FVC at baseline was 72.0 (14.9) % predicted. The proportions of patients with RA-ILD progression at weeks 2, 4, 6, 12, 24, 36 and 52 were 12.8%, 12.8%, 25.5%, 23.4%, 40.4%, 51.1% and 55.3%. Kaplan-Meier estimates of time to ILD progression are shown in the Figure.

Conclusion: In clinical trials in patients with SSc-ILD and RA-ILD, a substantial proportion of patients showed ILD progression over as little as three months. Patients with SSc-ILD and RA-ILD should be monitored more frequently than annually, including patients more than 1-2 years after diagnosis, to enable early detection of ILD progression and timely decision-making about treatment.

Supporting image 1

Figure. Kaplan-Meier estimates of time to absolute decline in FVC % predicted ≥5% or death over 52 weeks in A) patients with SSc-ILD who received placebo in the SENSCIS trial and B) patients with progressive fibrosing RA-ILD who received placebo in the INBUILD trial.

Supporting image 2

Disclosures: O. Distler: 4P-Pharma, 2, “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143), 10, AbbVie, 2, Acceleron, 2, Alcimed, 2, Altavant Sciences, 2, Amgen, 2, AnaMar, 2, Arxx, 2, AstraZeneca, 2, Bayer, 2, 6, Blade Therapeutics, 2, Boehringer Ingelheim, 2, 5, 6, Citrus AG, 12, Co-founder, Corbus Pharmaceuticals, 2, CSL Behring, 2, EMD Serono, 2, ERS/EULAR Guidelines, 12, Co-Chair, EUSTAR, 12, President, FOREUM Foundation, 12, Chair of Executive Committee, Galapagos, 2, Glenmark, 2, Gossamer, 2, Hartmann Müller Foundation, 12, Member Board of Trustees, Horizon, 2, Janssen, 2, 6, Kymera, 2, 5, Lupin, 2, Medscape, 2, 6, Merck/MSD, 2, Miltenyi Biotec, 2, Mitsubishi Tanabe, 2, 5, Nkarta Inc., 2, Novartis, 2, Orion, 2, Prometheus Biosciences, 2, Redxpharma, 2, Roivant, 2, Swiss Academy of Medical Sciences, 12, Senat Member, Swiss Clinical Quality Management in Rheumatic Diseases, 12, Member Board of Trustees, Topadur, 2, UCB, 2; M. Alves: Boehringer Ingelheim, 3; G. Toenges: Boehringer-Ingelheim, 3; A. Hoffmann-Vold: Arxx Therapeutics, 2, Boehringer Ingelheim, 2, 5, 6, 12, Support for travel, Genentech, 2, Janssen, 2, 5, 6, Medscape, 2, 6, 12, Support for travel, Merck/MSD, 2, Novartis, 6, Pliant Therapeutics, 2, Roche, 2, 6, 12, Support for travel, Werfen, 2.

To cite this abstract in AMA style:

Distler O, Alves M, Toenges G, Hoffmann-Vold A. Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/patients-with-interstitial-lung-disease-due-to-systemic-sclerosis-or-rheumatoid-arthritis-need-monitoring-more-frequently-than-annually/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-interstitial-lung-disease-due-to-systemic-sclerosis-or-rheumatoid-arthritis-need-monitoring-more-frequently-than-annually/